The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
Identifying Patients Suitable for Adjuvant Neratinib
Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.
Watch
Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo
July 12th 2023Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.
Watch
Treatment Guidelines on Fertility Preservation in Breast Cancer
Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.
Watch
Monitoring Patients With Breast Cancer Receiving OFS
A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .
Watch
Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer
VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.
Watch
Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer
July 10th 2023Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.
Read More
CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer
July 8th 2023Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.
Read More
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Read More
Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen
Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.
Watch
How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?
Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
Watch
Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer
July 5th 2023Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Watch
Factors Informing the Selection and Use of OFS in Breast Cancer
Expert perspectives on the appropriate selection and use of OFS in premenopausal patients with breast cancer.
Watch
Data From the SOFT and TEXT Trials: Combination Therapy With OFS in Breast Cancer
Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).
Watch
Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Watch
Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.
Watch
Dr Coopey on the Benefits of Axillary Surgery Omission or De-Escalation in Breast Cancer
June 29th 2023Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.
Watch